Somatostatin analogues improve health‐related quality of life in polycystic liver disease: a pooled analysis of two randomised, placebo‐controlled trials
Alimentary Pharmacology & Therapeutics2015Vol. 42(5), pp. 591–598
Citations Over TimeTop 10% of 2015 papers
Myrte K. Neijenhuis, Tom J.G. Gevers, Frank Nevens, Marie C. Hogan, Vicente E. Torres, Wietske Kievit, Joost P.H. Drenth
Abstract
Somatostatin analogues improve HRQL in symptomatic polycystic liver disease. Halting the progressive nature of polycystic liver disease is necessary to prevent further decline of HRQL in severe hepatomegaly.
Related Papers
- → Massive Hepatomegaly in Adult Polycystic Liver Disease(1988)86 cited
- [Polycystic liver disease without autosomal dominant polycystic kidney disease].(2004)
- → Autosomal dominant polycystic liver disease: a second family(1982)35 cited
- → 72 RAPAMYCIN INHIBITS CYST GROWTH, IGF-1-MEDIATED VEGF SECRETION AND CELL PROLIFERATION IN POLYCYSTIN-2 DEFECTIVE MICE, A MODEL FOR POLYCYSTIC LIVER DISEASE (PLD) ASSOCIATED TO ADULT-DOMINANT-POLYCYSTIC-KIDNEY-DISEASE (ADPKD)(2009)
- → Fígado policístico - relato de caso / Polycystic liver - case report(2021)